• Duration from initiating chemotherapy to the time presenting the nadir of platelet count [ Time Frame: Up to the end of Cycle 1 (each cycle is 21 or 28 days) ]
• Proportion of subjects who do not require platelet transfusion or platelet boosting therapy (rhTPO or rhIL11) [ Time Frame: Up to the end of Cycle 1 (each cycle is 21 or 28 days) ]
• Proportion of subjects who do not require dose reduction in chemotherapy by >20% [ Time Frame: Up to the end of Cycle 2 (each cycle is 21 or 28 days) ]
• Proportion of subjects who do not require chemotherapy delay by >4 days [ Time Frame: Up to the end of Cycle 2 (each cycle is 21 or 28 days) ]

• Drug: Hetrombopag
  Hetrombopag oral tablet 5mg once daily for 14 days from 7 days prior to chemotherapy treatment.
• Drug: Placebo
  Placebo oral tablet (vehicle) 5mg once daily for 14 days from 7 days prior to chemotherapy treatment.

• Experimental: Hetrombopag treatment
  Study is 2:1 randomization ratio (hetrombopag to placebo).
  Intervention: Drug: Hetrombopag
• Placebo Comparator: Placebo treatment
  Study is 2:1 randomization ratio (hetrombopag to placebo).
  Intervention: Drug: Placebo

Inclusion Criteria:

• Men and women, 18-75 years of age;
• Participant with a confirmed diagnosis of solid tumor or lymphoma by histopathological or cytological examination receiving a chemotherapy regimen given in a 21 or 28-day cycle, including 1 or more of the following agents or class of agents: Antimetabolie Antineoplastic agents including gemcitabine, Antitumor Platinum drugs including Carboplatin or cisplatin, Anthracycline Alkylating agent, Alkylating agent or other chemotherapy which could induce thrombocytopenia;
• Participant experienced moderate thrombocytopenia, defined as two platelet counts within 30×109-75×109/L measured at least 24 h apart, during the previous chemotherapy cycle;
• In the previous day before dosing of Hemtrombopag (Day -1), subjects has a platelet count within 100×109-200×109/L, neutrophil count≥1.5×109/L, haemoglobin≥90g/L;
• Subject has a life expectancy≥12 weeks at screening and is able to receive at least two additional cycles of the current chemotherapy regimen when screening;
• ECOG performance status 0-1;
• Subjects of childbearing potential must agree to use a highly effective method of contraception, except subjects with surgically sterile;
• Subject is willing to participate in the study, and Subject must provide written informed consent.

Exclusion Criteria:

• Subject has experienced thrombocytopenia due to any etiology other than chemotherapy within 6 months of Screening;
• Subject has any history of hematologic diseases other than lymphoma and CIT;
• Solid tumor with invasion of bone marrow;
• Subject has received radiotherapy;
• Subject has a history of arterial or venous thrombosis within 6 months of Screening;
• Subject has a history of significant cardiovascular disease (eg, congestive heart failure New York Heart Association Grade 3/4, arrhythmia known to increase the risk of thromboembolic events (eg, atrial fibrillation), coronary artery stent placement, angioplasty, or coronary artery bypass graft;
• Subject has previously received a thrombopoietin receptor agonist (eg, eltrombopag), rhTPO or rhIL11 for the treatment of CIT;